Table 2.
Incidence density of VR-Efm and MRSA
| Year/Period | Total patient-days | Number of VR-Efm Isolates (n) | Cases of VR-Efm per 100,000 patient days | Number of MRSA Isolates (n) | Cases of MRSA per 100,000 patient days |
|---|---|---|---|---|---|
| 2019 | 559,794 | 1 | 0.18 | 196 | 35.01 |
| 2020 | 432,063 | 1 | 0.23 | 224 | 51.84 |
| 2021 | 479,973 | 2 | 0.42 | 274 | 57.09 |
| 2022 | 431,681 | 4 | 0.93 | 145 | 33.59 |
| 2023 | 551,141 | 16 | 2.90 | 151 | 27.40 |
| 2024 | 592,464 | 15 | 2.53 | 259 | 43.72 |
| 2025 Q1-Q2 | 231,946 | 12 | 5.17 | 107 | 46.13 |
VR-Efm: vancomycin-resistant Enterococcus faecium. MRSA: methicillin-resistant Staphylococcus aureus. Q: quarter